Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07090785
PHASE1

A Study of LY4088044 in Healthy Participants

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate how well LY4088044 is tolerated and what side effects may occur in healthy participants. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4088044 gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 92 weeks for Parts A, B, and C, excluding screening.

Official title: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4088044 in Healthy Participants.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

104

Start Date

2025-07-24

Completion Date

2027-07

Last Updated

2026-03-02

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

LY4088044

Administered IV

DRUG

LY4088044

Administered SC

DRUG

Placebo

Administered IV

DRUG

Placebo

Administered SC

Locations (6)

Collaborative Neuroscience Network - CNS

Los Alamitos, California, United States

ICON

Lenexa, Kansas, United States

ICON Early Phase Services

San Antonio, Texas, United States

ICON

Salt Lake City, Utah, United States

New Zealand Clinical Research Christchurch

Christchurch, New Zealand

Lilly Centre for Clinical Pharmacology

Singapore, Singapore